$SCNX
Scienture Holdings, Inc. Stock $scnx

$scnx Overview Financials Valuation SEC Filings Company Website

2024 Q4 Form 10-Q Financial Statement

#000149315224043756 Filed on November 06, 2024

Income Statement

Concept	2024 Q4	2024 Q3	2023 Q4
Revenue		$64.86K	$2.352M
YoY Change		-96.85%	-6.98%
Cost Of Revenue		$60.98K	$4.601M
YoY Change		-82.75%	366.47%
Gross Profit		$3.883K	-$2.249M
YoY Change		-99.77%	-245.77%
Gross Profit Margin		5.99%	-95.59%
Selling, General & Admin			$3.944M
YoY Change			116.66%
% of Gross Profit
Research & Development		$1.254M
YoY Change
% of Gross Profit		32294.18%
Depreciation & Amortization			$499.8K
YoY Change			17623.05%
% of Gross Profit
Operating Expenses		$3.502M	$3.944M
YoY Change		37.34%	116.66%
Operating Profit		-$3.498M	-$6.193M
YoY Change		313.87%	2128.92%
Interest Expense			-$703.4K
YoY Change			284.41%
% of Operating Profit
Other Income/Expense, Net		$314.2K	$309.4K
YoY Change		-53.35%	-62.52%
Pretax Income			-$11.72M
YoY Change			799.13%
Income Tax
% Of Pretax Income
Net Earnings		-$3.184M	-$11.72M
YoY Change		-9.69%	1166.33%
Net Earnings / Revenue		-4908.34%	-498.04%
Basic Earnings Per Share		-$1.34
Diluted Earnings Per Share		-$1.34	-$12.57
COMMON SHARES
Basic Shares Outstanding	8.577M shares	1.459M shares
Diluted Shares Outstanding		2.374M shares

Balance Sheet

Concept	2024 Q3	2023 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments		$151.9K
YoY Change		-86.6%
Cash & Equivalents	$579.1K	$151.9K
Short-Term Investments
Other Short-Term Assets		$107.8K
YoY Change		-2.86%
Inventory	$7.884K	$968.00
Prepaid Expenses		$107.8K
Receivables	$10.43K	$821.8K
Other Receivables	$4.506M	$1.671M
Total Short-Term Assets	$7.256M	$2.753M
YoY Change	30.79%	31.53%
LONG-TERM ASSETS
Property, Plant & Equipment	$17.50K	$277.0K
YoY Change	-93.92%	324.77%
Goodwill	$7.849M
YoY Change	53.02%
Intangibles	$76.40M	$8.963M
YoY Change	708.33%
Long-Term Investments
YoY Change
Other Assets		$10.53K
YoY Change		-78.52%
Total Long-Term Assets	$87.00M	$9.780M
YoY Change	440.19%	504.85%
TOTAL ASSETS
Total Short-Term Assets	$7.256M	$2.753M
Total Long-Term Assets	$87.00M	$9.780M
Total Assets	$94.26M	$12.53M
YoY Change	335.3%	237.81%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.904M	$2.082M
YoY Change	118.58%	185.54%
Accrued Expenses	$1.043M	$401.0K
YoY Change	170.16%	38.27%
Deferred Revenue
YoY Change
Short-Term Debt		$0.00
YoY Change
Long-Term Debt Due		$6.530M
YoY Change		3817.92%
Total Short-Term Liabilities	$5.413M	$11.56M
YoY Change	-40.46%	438.31%
LONG-TERM LIABILITIES
Long-Term Debt		$25.00K
YoY Change		-92.5%
Other Long-Term Liabilities		$409.2K
YoY Change		-53.87%
Total Long-Term Liabilities		$434.2K
YoY Change		-51.05%
TOTAL LIABILITIES
Total Short-Term Liabilities	$5.413M	$11.56M
Total Long-Term Liabilities		$434.2K
Total Liabilities	$9.128M	$11.99M
YoY Change	-9.57%	256.1%
SHAREHOLDERS EQUITY
Retained Earnings	-$31.88M	-$33.25M
YoY Change	48.06%	68.76%
Common Stock	$86.00	$9.00
YoY Change	975.0%	-90.91%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$85.13M	$542.4K
YoY Change
Total Liabilities & Shareholders Equity	$94.26M	$12.53M
YoY Change	335.3%	237.81%

Cashflow Statement

Concept	2024 Q3	2023 Q4
OPERATING ACTIVITIES
Net Income	-$3.184M	-$11.72M
YoY Change	-9.69%	1166.33%
Depreciation, Depletion And Amortization		$499.8K
YoY Change		17623.05%
Cash From Operating Activities		-$867.5K
YoY Change		-170.53%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities		-$350.0K
YoY Change
Cash From Investing Activities		-$350.0K
YoY Change		204.48%
FINANCING ACTIVITIES
Cash Dividend Paid	$2.188M
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities		1.335M
YoY Change		-540.45%
NET CHANGE
Cash From Operating Activities		-867.5K
Cash From Investing Activities		-350.0K
Cash From Financing Activities		1.335M
Net Change In Cash		117.9K
YoY Change		-85.48%
FREE CASH FLOW
Cash From Operating Activities		-$867.5K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Entity Central Index Key EntityCentralIndexKey	0001382574
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2024-09-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-39199
	dei	Entity Registrant Name EntityRegistrantName	Scienture Holdings, Inc.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	46-3673928
	dei	Entity Address Address Line1 EntityAddressAddressLine1	6308 Benjamin Rd
CY2024Q3	us-gaap	Inventory Net InventoryNet	7884	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	968	usd
CY2023Q4	us-gaap	Assets Of Disposal Group Including Discontinued Operation Current AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent	176355	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	2753063	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	7500	usd
CY2023Q4	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	10531	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent		usd
CY2023Q4	us-gaap	Deferred Offering Costs DeferredOfferingCosts		usd
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill		usd
CY2023Q4	us-gaap	Goodwill Goodwill		usd
CY2023Q4	us-gaap	Long Term Investments LongTermInvestments		usd
CY2024Q3	us-gaap	Disposal Group Including Discontinued Operation Assets Noncurrent DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent		usd
CY2024Q3	SCNX	Contingent Funding Liabilities Current ContingentFundingLiabilitiesCurrent		usd
CY2023Q4	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable		usd
CY2023Q4	SCNX	Development Agreement Liability DevelopmentAgreementLiability		usd
CY2024Q3	us-gaap	Liabilities Of Disposal Group Including Discontinued Operation Noncurrent LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent		usd
CY2024Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense		usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense		usd
CY2023Q3	us-gaap	Interest Income Other InterestIncomeOther		usd
CY2024Q3	SCNX	Loss On Disposition Of Assets1 LossOnDispositionOfAssets1		usd
CY2023Q3	SCNX	Loss On Disposition Of Assets1 LossOnDispositionOfAssets1		usd
CY2024Q3	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax		usd
CY2024Q3	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
CY2024Q3	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
CY2024Q3	us-gaap	Stock Issued During Period Value Conversion Of Units StockIssuedDuringPeriodValueConversionOfUnits		usd
CY2024Q3	SCNX	Stock Issued During Period Value Conversion Of Preferred Stock Into Common Stock StockIssuedDuringPeriodValueConversionOfPreferredStockIntoCommonStock		usd
CY2024Q3	SCNX	Stock Issued During Period Value Warrants Exercised For Shares StockIssuedDuringPeriodValueWarrantsExercisedForShares		usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium		usd
	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables		usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment		usd
	us-gaap	Payments For Proceeds From Investments PaymentsForProceedsFromInvestments		usd
	us-gaap	Proceeds From Short Term Debt ProceedsFromShortTermDebt		usd
	us-gaap	Proceeds From Repayments Of Debt ProceedsFromRepaymentsOfDebt		usd
	us-gaap	Payments Of Dividends PaymentsOfDividends		usd
	SCNX	Proceeds From Sale Of Future Revenue ProceedsFromSaleOfFutureRevenue		usd
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt		usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised		usd
	us-gaap	Interest Paid Net InterestPaidNet		usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
	us-gaap	Stock Issued1 StockIssued1		usd
	SCNX	Assets Acquired In Connection With Merger AssetsAcquiredInConnectionWithMerger		usd
	SCNX	Liabilities Assumed In Connection With Merger LiabilitiesAssumedInConnectionWithMerger		usd
	SCNX	Deferred Offering Cost DeferredOfferingCost		usd
	SCNX	Warrants Issued With Convertible Note WarrantsIssuedWithConvertibleNote		usd
	us-gaap	Notes Issued1 NotesIssued1		usd
	SCNX	Disposition Of Related Party Assets DispositionOfRelatedPartyAssets		usd
CY2024Q3	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax		usd
CY2024Q3	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
CY2024Q3	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
CY2024Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2023Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2024Q3	us-gaap	Disposal Group Including Discontinued Operation Revenue DisposalGroupIncludingDiscontinuedOperationRevenue		usd
CY2024Q3	us-gaap	Disposal Group Including Discontinued Operation Costs Of Goods Sold DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold		usd
CY2024Q3	us-gaap	Disposal Group Including Discontinued Operation Gross Profit Loss DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss		usd
CY2024Q3	SCNX	Disposal Group Including Discontinued Operation Wages And Salary Expense DisposalGroupIncludingDiscontinuedOperationWagesAndSalaryExpense		usd
CY2024Q3	SCNX	Disposal Group Including Discontinued Operation Professional Expense DisposalGroupIncludingDiscontinuedOperationProfessionalExpense		usd
CY2024Q3	SCNX	Disposal Group Including Discontinued Operation Technology Expense DisposalGroupIncludingDiscontinuedOperationTechnologyExpense		usd
CY2024Q3	us-gaap	Disposal Group Including Discontinued Operation General And Administrative Expense DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense		usd
CY2024Q3	us-gaap	Disposal Group Including Discontinued Operation Operating Expense DisposalGroupIncludingDiscontinuedOperationOperatingExpense		usd
CY2024Q3	us-gaap	Disposal Group Including Discontinued Operation Operating Income Loss DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss		usd
CY2024Q3	SCNX	Disposal Group Including Discontinued Operation Gain Loss On Dispositions DisposalGroupIncludingDiscontinuedOperationGainLossOnDispositions		usd
CY2024Q3	SCNX	Disposal Group Including Discontinued Operation Other Income Loss From Discontinued Opeations DisposalGroupIncludingDiscontinuedOperationOtherIncomeLossFromDiscontinuedOpeations		usd
	us-gaap	Disposal Group Including Discontinued Operation Costs Of Goods Sold DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold		usd
CY2023Q4	SCNX	Share Based Compensation Arrangement By Share Based Payment Award Non Options Equity Instrument Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentOutstandingIntrinsicValue		usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeitures And Expirations ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations		shares
	SCNX	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeited In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice
	dei	Document Type DocumentType	10-Q
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 708
	dei	Entity Address City Or Town EntityAddressCityOrTown	Tampa
	dei	Entity Address State Or Province EntityAddressStateOrProvince	FL
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	33634
	dei	City Area Code CityAreaCode	(800)
	dei	Local Phone Number LocalPhoneNumber	261-0281
	dei	Security12b Title Security12bTitle	Common Stock, $0.00001 Par Value Per Share
	dei	Trading Symbol TradingSymbol	SCNX
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
	dei	Entity Shell Company EntityShellCompany	false
CY2024Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	8576795	shares
CY2024Q3	us-gaap	Cash Cash	579103	usd
CY2023Q4	us-gaap	Cash Cash	314	usd
CY2024Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	10430	usd
CY2024Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	775113	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	50724	usd
CY2024Q3	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	4505797	usd
CY2023Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	1224702	usd
CY2024Q3	us-gaap	Deferred Offering Costs DeferredOfferingCosts	69444	usd
CY2024Q3	us-gaap	Assets Of Disposal Group Including Discontinued Operation Current AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent	8145	usd
CY2024Q3	us-gaap	Assets Current AssetsCurrent	7255916	usd
CY2024Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	17500	usd
CY2024Q3	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	22039	usd
CY2024Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	76400000	usd
CY2024Q3	us-gaap	Goodwill Goodwill	7848747	usd
CY2024Q3	us-gaap	Long Term Investments LongTermInvestments	2500000	usd
CY2024Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	215491	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	191216	usd
CY2023Q4	us-gaap	Disposal Group Including Discontinued Operation Assets Noncurrent DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent	9570603	usd
CY2024Q3	us-gaap	Assets Assets	94259693	usd
CY2023Q4	us-gaap	Assets Assets	12532913	usd
CY2024Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	2904081	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1463014	usd
CY2024Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1042892	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	160214	usd
CY2024Q3	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	5441	usd
CY2023Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	67831	usd
CY2023Q4	SCNX	Contingent Funding Liabilities Current ContingentFundingLiabilitiesCurrent	1246346	usd
CY2024Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	60882	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	32595	usd
CY2024Q3	SCNX	Warrant Liability WarrantLiability	1129796	usd
CY2023Q4	SCNX	Warrant Liability WarrantLiability	736953	usd
CY2024Q3	us-gaap	Liabilities Of Disposal Group Including Discontinued Operation Current LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent	5346	usd
CY2023Q4	us-gaap	Liabilities Of Disposal Group Including Discontinued Operation Current LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent	7849402	usd
CY2024Q3	us-gaap	Liabilities Current LiabilitiesCurrent	5413438	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	11556355	usd
CY2024Q3	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	2255848	usd
CY2024Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	173366	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	176909	usd
CY2024Q3	SCNX	Development Agreement Liability DevelopmentAgreementLiability	1285000	usd
CY2023Q4	us-gaap	Liabilities Of Disposal Group Including Discontinued Operation Noncurrent LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent	257296	usd
CY2024Q3	us-gaap	Liabilities Liabilities	9127652	usd
CY2023Q4	us-gaap	Liabilities Liabilities	11990560	usd
CY2024Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2024Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2024Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	8605366	shares
CY2024Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	8605366	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	905008	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	905008	shares
CY2024Q3	us-gaap	Common Stock Value CommonStockValue	86	usd
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	9	usd
CY2024Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	117008196	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	33788284	usd
CY2024Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-31876241	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-33245940	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	85132041	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	542353	usd
CY2024Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	94259693	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	12532913	usd
CY2024Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	64861	usd
CY2023Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	392286	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	83560	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1235168	usd
CY2024Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	60978	usd
CY2023Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	352694	usd
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	80380	usd
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1072178	usd
CY2024Q3	us-gaap	Gross Profit GrossProfit	3883	usd
CY2023Q3	us-gaap	Gross Profit GrossProfit	39592	usd
	us-gaap	Gross Profit GrossProfit	3180	usd
	us-gaap	Gross Profit GrossProfit	162990	usd
CY2024Q3	us-gaap	Salaries And Wages SalariesAndWages	708977	usd
CY2023Q3	us-gaap	Salaries And Wages SalariesAndWages	7342	usd
	us-gaap	Salaries And Wages SalariesAndWages	1243621	usd
	us-gaap	Salaries And Wages SalariesAndWages	345235	usd
CY2024Q3	us-gaap	Professional Fees ProfessionalFees	593364	usd
CY2023Q3	us-gaap	Professional Fees ProfessionalFees	295497	usd
	us-gaap	Professional Fees ProfessionalFees	1282053	usd
	us-gaap	Professional Fees ProfessionalFees	619794	usd
CY2024Q3	us-gaap	Litigation Settlement Expense LitigationSettlementExpense	619227	usd
CY2023Q3	us-gaap	Litigation Settlement Expense LitigationSettlementExpense	409480	usd
	us-gaap	Litigation Settlement Expense LitigationSettlementExpense	1129982	usd
	us-gaap	Litigation Settlement Expense LitigationSettlementExpense	782495	usd
CY2024Q3	SCNX	Technology Expense TechnologyExpense	157474	usd
CY2023Q3	SCNX	Technology Expense TechnologyExpense	22071	usd
	SCNX	Technology Expense TechnologyExpense	295763	usd
	SCNX	Technology Expense TechnologyExpense	74946	usd
CY2024Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	168649	usd
CY2023Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	66880	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5284231	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	483374	usd
CY2024Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1253983	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1253983	usd
CY2024Q3	us-gaap	Operating Expenses OperatingExpenses	3501674	usd
CY2023Q3	us-gaap	Operating Expenses OperatingExpenses	801270	usd
	us-gaap	Operating Expenses OperatingExpenses	10489633	usd
	us-gaap	Operating Expenses OperatingExpenses	2305844	usd
CY2024Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-3497791	usd
CY2023Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-761678	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-10486453	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-2142854	usd
CY2024Q3	SCNX	Change In Fair Value Of Warrant Liability ChangeInFairValueOfWarrantLiability	502178	usd
CY2023Q3	SCNX	Change In Fair Value Of Warrant Liability ChangeInFairValueOfWarrantLiability	925320	usd
	SCNX	Change In Fair Value Of Warrant Liability ChangeInFairValueOfWarrantLiability	-392843	usd
	SCNX	Change In Fair Value Of Warrant Liability ChangeInFairValueOfWarrantLiability	-443308	usd
CY2024Q3	us-gaap	Interest Income Other InterestIncomeOther	29445	usd
	us-gaap	Interest Income Other InterestIncomeOther	133397	usd
	us-gaap	Interest Income Other InterestIncomeOther	4198	usd
	SCNX	Loss On Disposition Of Assets1 LossOnDispositionOfAssets1	-374968	usd
	SCNX	Loss On Disposition Of Assets1 LossOnDispositionOfAssets1	-352244	usd
CY2024Q3	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	217433	usd
CY2023Q3	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	251778	usd
	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	320897	usd
	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	494904	usd
CY2024Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	314190	usd
CY2023Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	673542	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-955311	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1286258	usd
CY2024Q3	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-3183601	usd
CY2023Q3	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-88136	usd
	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-11441764	usd
	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-3429112	usd
CY2023Q3	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-3436978	usd
	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	27670294	usd
	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-2748833	usd
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	-3183601	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-3525114	usd
	us-gaap	Net Income Loss NetIncomeLoss	16228530	usd
	us-gaap	Net Income Loss NetIncomeLoss	-6177945	usd
CY2024Q3	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-1.34
CY2023Q3	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.11
	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-7.10
	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-4.84
CY2024Q3	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-1.34
CY2023Q3	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-0.11
	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-7.10
	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-4.84
CY2023Q3	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	-4.46
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	17.17
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	-3.88
CY2023Q3	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	-1.45
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	14.64
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	-1.20
CY2024Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.34
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-4.57
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	10.07
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-8.72
CY2024Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.34
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-4.57
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	8.59
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-8.72
CY2024Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	2373848	shares
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	771192	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1611221	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	708116	shares
CY2024Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	2373848	shares
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	2363233	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1889504	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	2300157	shares
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	342867	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	63486	usd
CY2023Q1	SCNX	Disposition Of Assets Related Party DispositionOfAssetsRelatedParty	912299	usd
CY2023Q1	SCNX	Stock Issued During Period Value Warrants Exercised For Cash StockIssuedDuringPeriodValueWarrantsExercisedForCash	7	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	14434	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-677953	usd
CY2023Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	655140	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	15813	usd
CY2023Q2	SCNX	Stock Issued During Period Value Warrants Exercised For Cash StockIssuedDuringPeriodValueWarrantsExercisedForCash	1615	usd
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	7783	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-1974878	usd
CY2023Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-1294527	usd
CY2023Q3	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	3761	usd
CY2023Q3	SCNX	Disposition Of Assets DispositionOfAssets	3875476	usd
CY2023Q3	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	12500089	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-3525114	usd
CY2023Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	11559685	usd
CY2023Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	542353	usd
CY2024Q1	us-gaap	Share Price SharePrice	8
CY2024Q1	us-gaap	Dividends Dividends	12671072	usd
CY2024Q1	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	4450919	usd
CY2024Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	9840	usd
CY2024Q1	SCNX	Stock Issued During Period Value Warrants Exercised For Cash StockIssuedDuringPeriodValueWarrantsExercisedForCash	16567	usd
CY2024Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	24266	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	21246033	usd
CY2024Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	13618906	usd
CY2024Q2	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	444	usd
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	-1833902	usd
CY2024Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	11785448	usd
CY2024Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	11785448	usd
CY2024Q3	us-gaap	Share Price SharePrice	1.50
CY2024Q3	us-gaap	Dividends Dividends	2187759	usd
CY2024Q3	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	78646184	usd
CY2024Q3	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	71332	usd
CY2024Q3	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	437	usd
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	-3183601	usd
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	-3183601	usd
CY2024Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	85132041	usd
CY2024Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	85132041	usd
	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-11441764	usd
	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-3429112	usd
	us-gaap	Depreciation Depreciation	2000	usd
	us-gaap	Depreciation Depreciation	8464	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	392843	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	443308	usd
	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	25147	usd
	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	25978	usd
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	4450919	usd
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	79299	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	13180	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	37302	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	325916	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	10430	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	212292	usd
	us-gaap	Increase Decrease In Prepaid Expenses Other IncreaseDecreaseInPrepaidExpensesOther	735897	usd
	us-gaap	Increase Decrease In Prepaid Expenses Other IncreaseDecreaseInPrepaidExpensesOther	138450	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	6916	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	39013	usd
	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	3281095	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-37141	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	6414	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	453969	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	854171	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-384900	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	43729	usd
	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	-62390	usd
	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	-5127	usd
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-10585173	usd
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-2036715	usd
	us-gaap	Cash Provided By Used In Operating Activities Discontinued Operations CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations	-770653	usd
	us-gaap	Cash Provided By Used In Operating Activities Discontinued Operations CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations	830638	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-11355826	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1206077	usd
	us-gaap	Cash Acquired From Acquisition CashAcquiredFromAcquisition	132976	usd
	us-gaap	Cash Acquired From Acquisition CashAcquiredFromAcquisition	5546	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	12000	usd
	us-gaap	Payments For Proceeds From Investments PaymentsForProceedsFromInvestments	2500000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-2379024	usd
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	5546	usd
	us-gaap	Cash Provided By Used In Investing Activities Discontinued Operations CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations	29931815	usd
	us-gaap	Cash Provided By Used In Investing Activities Discontinued Operations CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations	68737	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	27552791	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	74283	usd
	us-gaap	Payment For Contingent Consideration Liability Financing Activities PaymentForContingentConsiderationLiabilityFinancingActivities	1246346	usd
	us-gaap	Payment For Contingent Consideration Liability Financing Activities PaymentForContingentConsiderationLiabilityFinancingActivities	1755688	usd
	us-gaap	Proceeds From Short Term Debt ProceedsFromShortTermDebt	200000	usd
	us-gaap	Proceeds From Repayments Of Debt ProceedsFromRepaymentsOfDebt	25000	usd
	us-gaap	Payments Of Dividends PaymentsOfDividends	14858831	usd
	SCNX	Proceeds From Sale Of Future Revenue ProceedsFromSaleOfFutureRevenue	2100000	usd
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	314000	usd
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	16567	usd
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	1622	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	9840	usd
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	-15764770	usd
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	570934	usd
	us-gaap	Cash Provided By Used In Financing Activities Discontinued Operations CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations	-5000	usd
	us-gaap	Cash Provided By Used In Financing Activities Discontinued Operations CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations	-500000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-15769770	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	70934	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	427195	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-1060860	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	151908	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	1094891	usd
CY2024Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	579103	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	34031	usd
	us-gaap	Interest Paid Net InterestPaidNet	243126	usd
	us-gaap	Stock Issued1 StockIssued1	78646184	usd
	SCNX	Assets Acquired In Connection With Merger AssetsAcquiredInConnectionWithMerger	194554	usd
	SCNX	Liabilities Assumed In Connection With Merger LiabilitiesAssumedInConnectionWithMerger	5797117	usd
	SCNX	Insurance Premium Financed InsurancePremiumFinanced	198245	usd
	SCNX	Insurance Premium Financed InsurancePremiumFinanced	306152	usd
	SCNX	Deferred Offering Cost DeferredOfferingCost	69444	usd
	SCNX	Warrants Issued With Convertible Note WarrantsIssuedWithConvertibleNote	71332	usd
	us-gaap	Notes Issued1 NotesIssued1	500000	usd
	SCNX	Disposition Of Related Party Assets DispositionOfRelatedPartyAssets	492030	usd
CY2023Q2	us-gaap	Stockholders Equity Note Stock Split StockholdersEquityNoteStockSplit	Effective June 21, 2023, the Company executed a 1:15 reverse stock split for stockholders of record on that date
CY2023Q2	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	1.00
CY2024Q3	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	4505797	usd
CY2023Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	1224702	usd
CY2024Q3	us-gaap	Deferred Offering Costs DeferredOfferingCosts	69444	usd
CY2024Q3	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	238594	shares
CY2024Q3	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	-3183601	usd
CY2023Q3	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	-88136	usd
	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	-11441764	usd
	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	-3429112	usd
CY2023Q3	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-3436978	usd
	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	27670294	usd
	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-2748833	usd
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	-3183601	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-3525114	usd
	us-gaap	Net Income Loss NetIncomeLoss	16228530	usd
	us-gaap	Net Income Loss NetIncomeLoss	-6177945	usd
CY2024Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	2373848	shares
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	771192	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1611221	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	708116	shares
CY2024Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	2373848	shares
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	2363233	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1889504	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	2300157	shares
CY2024Q3	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-1.34
CY2023Q3	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.11
	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-7.10
	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-4.84
CY2024Q3	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-1.34
CY2023Q3	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-0.11
	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-7.10
	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-4.84
CY2023Q3	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	-4.46
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	17.17
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	-3.88
CY2023Q3	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	-1.45
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	14.64
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	-1.20
CY2024Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.34
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-4.57
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	10.07
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-8.72
CY2024Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.34
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-4.57
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	8.59
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-8.72
CY2024Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-31876241	usd
CY2024Q3	us-gaap	Cash Cash	579103	usd
	us-gaap	Business Acquisitions Pro Forma Revenue BusinessAcquisitionsProFormaRevenue	83560	usd
	us-gaap	Business Acquisitions Pro Forma Revenue BusinessAcquisitionsProFormaRevenue	1735168	usd
	us-gaap	Business Acquisitions Pro Forma Income Loss From Continuing Operations Before Changes In Accounting And Extraordinary Items Net Of Tax BusinessAcquisitionsProFormaIncomeLossFromContinuingOperationsBeforeChangesInAccountingAndExtraordinaryItemsNetOfTax	-16722735	usd
	us-gaap	Business Acquisitions Pro Forma Income Loss From Continuing Operations Before Changes In Accounting And Extraordinary Items Net Of Tax BusinessAcquisitionsProFormaIncomeLossFromContinuingOperationsBeforeChangesInAccountingAndExtraordinaryItemsNetOfTax	-4644587	usd
	SCNX	Business Acquisition Pro Forma Income Loss From Continuing Operations Before Changes In Accounting And Extraordinary Items Net Of Tax Per Share BusinessAcquisitionProFormaIncomeLossFromContinuingOperationsBeforeChangesInAccountingAndExtraordinaryItemsNetOfTaxPerShare	-10.38
	SCNX	Business Acquisition Pro Forma Income Loss From Continuing Operations Before Changes In Accounting And Extraordinary Items Net Of Tax Per Share BusinessAcquisitionProFormaIncomeLossFromContinuingOperationsBeforeChangesInAccountingAndExtraordinaryItemsNetOfTaxPerShare	-6.56
CY2023	SCNX	Gain Loss On Disposal Of Assets GainLossOnDisposalOfAssets	3300225	usd
CY2023Q3	us-gaap	Disposal Group Including Discontinued Operation Revenue DisposalGroupIncludingDiscontinuedOperationRevenue	1789980	usd
CY2023Q3	us-gaap	Disposal Group Including Discontinued Operation Costs Of Goods Sold DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold	128427	usd
CY2023Q3	us-gaap	Disposal Group Including Discontinued Operation Gross Profit Loss DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss	1661553	usd
CY2023Q3	SCNX	Disposal Group Including Discontinued Operation Wages And Salary Expense DisposalGroupIncludingDiscontinuedOperationWagesAndSalaryExpense	849796	usd
CY2023Q3	SCNX	Disposal Group Including Discontinued Operation Professional Expense DisposalGroupIncludingDiscontinuedOperationProfessionalExpense	140875	usd
CY2023Q3	SCNX	Disposal Group Including Discontinued Operation Technology Expense DisposalGroupIncludingDiscontinuedOperationTechnologyExpense	345840	usd
CY2023Q3	us-gaap	Disposal Group Including Discontinued Operation General And Administrative Expense DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense	552244	usd
CY2023Q3	us-gaap	Disposal Group Including Discontinued Operation Operating Expense DisposalGroupIncludingDiscontinuedOperationOperatingExpense	1888755	usd
CY2023Q3	us-gaap	Disposal Group Including Discontinued Operation Operating Income Loss DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss	-227202	usd
CY2023Q3	SCNX	Disposal Group Including Discontinued Operation Gain Loss On Dispositions DisposalGroupIncludingDiscontinuedOperationGainLossOnDispositions	-3209776	usd
CY2023Q3	SCNX	Disposal Group Including Discontinued Operation Other Income Loss From Discontinued Opeations DisposalGroupIncludingDiscontinuedOperationOtherIncomeLossFromDiscontinuedOpeations	-3436978	usd
	us-gaap	Disposal Group Including Discontinued Operation Revenue DisposalGroupIncludingDiscontinuedOperationRevenue	970808	usd
	us-gaap	Disposal Group Including Discontinued Operation Revenue DisposalGroupIncludingDiscontinuedOperationRevenue	5445924	usd
	us-gaap	Disposal Group Including Discontinued Operation Costs Of Goods Sold DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold	705962	usd
	us-gaap	Disposal Group Including Discontinued Operation Gross Profit Loss DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss	970808	usd
	us-gaap	Disposal Group Including Discontinued Operation Gross Profit Loss DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss	4739962	usd
	SCNX	Disposal Group Including Discontinued Operation Wages And Salary Expense DisposalGroupIncludingDiscontinuedOperationWagesAndSalaryExpense	713599	usd
	SCNX	Disposal Group Including Discontinued Operation Wages And Salary Expense DisposalGroupIncludingDiscontinuedOperationWagesAndSalaryExpense	2238759	usd
	SCNX	Disposal Group Including Discontinued Operation Professional Expense DisposalGroupIncludingDiscontinuedOperationProfessionalExpense	62160	usd
	SCNX	Disposal Group Including Discontinued Operation Professional Expense DisposalGroupIncludingDiscontinuedOperationProfessionalExpense	185863	usd
	SCNX	Disposal Group Including Discontinued Operation Technology Expense DisposalGroupIncludingDiscontinuedOperationTechnologyExpense	88904	usd
	SCNX	Disposal Group Including Discontinued Operation Technology Expense DisposalGroupIncludingDiscontinuedOperationTechnologyExpense	1036276	usd
	us-gaap	Disposal Group Including Discontinued Operation General And Administrative Expense DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense	38055	usd
	us-gaap	Disposal Group Including Discontinued Operation General And Administrative Expense DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense	818120	usd
	us-gaap	Disposal Group Including Discontinued Operation Operating Expense DisposalGroupIncludingDiscontinuedOperationOperatingExpense	902718	usd
	us-gaap	Disposal Group Including Discontinued Operation Operating Expense DisposalGroupIncludingDiscontinuedOperationOperatingExpense	4279019	usd
	us-gaap	Disposal Group Including Discontinued Operation Operating Income Loss DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss	68090	usd
	us-gaap	Disposal Group Including Discontinued Operation Operating Income Loss DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss	460943	usd
	SCNX	Disposal Group Including Discontinued Operation Gain Loss On Dispositions DisposalGroupIncludingDiscontinuedOperationGainLossOnDispositions	27602204	usd
	SCNX	Disposal Group Including Discontinued Operation Gain Loss On Dispositions DisposalGroupIncludingDiscontinuedOperationGainLossOnDispositions	-3209776	usd
	SCNX	Disposal Group Including Discontinued Operation Other Income Loss From Discontinued Opeations DisposalGroupIncludingDiscontinuedOperationOtherIncomeLossFromDiscontinuedOpeations	27670294	usd
	SCNX	Disposal Group Including Discontinued Operation Other Income Loss From Discontinued Opeations DisposalGroupIncludingDiscontinuedOperationOtherIncomeLossFromDiscontinuedOpeations	-2748833	usd
CY2024Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	64861	usd
CY2023Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	392286	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	83560	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1235168	usd
CY2024Q3	us-gaap	Inventory Finished Goods InventoryFinishedGoods	7884	usd
CY2023Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	968	usd
CY2024Q3	us-gaap	Inventory Net InventoryNet	7884	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	968	usd
CY2023Q2	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	Effective June 21, 2023, the Company executed a 1:15 reverse stock split for stockholders of record on that date
CY2023Q2	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	1
CY2024Q3	us-gaap	Payments For Proceeds From Previous Acquisition PaymentsForProceedsFromPreviousAcquisition	78646184	usd
CY2024Q1	us-gaap	Dividends Payable Amount Per Share DividendsPayableAmountPerShare	8.00
CY2024Q1	us-gaap	Payments Of Dividends PaymentsOfDividends	12671072	usd
CY2024Q3	us-gaap	Dividends Payable Amount Per Share DividendsPayableAmountPerShare	1.50
CY2024Q3	us-gaap	Payments Of Dividends PaymentsOfDividends	2187759	usd
CY2024Q3	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	1129796	usd
CY2023Q3	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	925320	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	443308	usd
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	218729	shares
CY2023Q4	SCNX	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice	19.62
CY2023	SCNX	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm	P3Y11M12D
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted	76923	shares
	SCNX	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice	9.36
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised	57058	shares
	SCNX	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice	8.25
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	238594	shares
CY2024Q3	SCNX	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice	19.02
	SCNX	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm	P3Y5M12D
CY2024Q3	SCNX	Share Based Compensation Arrangement By Share Based Payment Award Non Options Equity Instrument Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentOutstandingIntrinsicValue	96311	usd
	SCNX	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercisable ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable	238594	shares
CY2024Q3	SCNX	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityExercisableWeightedAverageExercisePrice	19.02
	SCNX	Sharebased Compensation Arrangement By Sharebased Payment Award Non Option Equity Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityExercisableWeightedAverageRemainingContractualTerm1	P3Y5M12D
CY2024Q3	SCNX	Share Based Compensation Arrangement By Share Based Payment Award Non Options Equity Instrument Exercisable Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentExercisableIntrinsicValue	96311	usd
CY2024Q3	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	437	usd
CY2023Q3	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	3761	usd
	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	25147	usd
	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	25978	usd
	us-gaap	Loss Contingency Disclosures LossContingencyDisclosures	<p id="xdx_80E_eus-gaap--LossContingencyDisclosures_zWAYxS5Lbtki" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 15 – <span id="xdx_828_zMmrzrY6KkKk">CONTINGENCIES</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Studebaker Defense Group, LLC</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In July 2020, the Company’s wholly-owned subsidiary, IPS, entered into an agreement with Studebaker Defense Group, LLC (“Studebaker”) wherein IPS would pay Studebaker a down payment of $<span id="xdx_905_ecustom--DownPayment_c20200701__20200731__dei--LegalEntityAxis__custom--IPSMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--StudebakerDefenseGroupLLCMember_zVtwVO4nNHv" title="Down payment">550,000</span> and Studebaker would deliver <span id="xdx_902_ecustom--NumberOfNitrileGlovesDelivered_uInteger_c20200813__20200814__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--StudebakerDefenseGroupLLCMember__dei--LegalEntityAxis__custom--IPSMember_zXyRC0K4nvBl" title="Number of nitrile gloves delivered">180,000</span> boxes of nitrile gloves by August 14, 2020. IPS wired the $<span id="xdx_907_eus-gaap--ProceedsFromSaleOfOtherProductiveAssets_c20200701__20200731__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--StudebakerDefenseGroupLLCMember__dei--LegalEntityAxis__custom--IPSMember_z25B9yP0Eh9l" title="Proceeds from sale of other productive assets">550,000</span> to Studebaker, but to date, Studebaker has not delivered the gloves or provided a refund of the deposit. In December 2020, the Company filed a complaint against Studebaker in Florida state court, Case No. 20-CA-010118 in the Circuit Court for the Thirteenth Judicial Circuit in Hillsborough County, for among other things, breach of contract. Studebaker did not answer the complaint, nor did counsel for Studebaker file an appearance. Accordingly, in February 2021, the Company filed for a default judgment; however, on March 22, 2021, counsel for Studebaker filed an appearance and shortly thereafter filed a motion to vacate the default judgment and dismiss the complaint on jurisdictional grounds. The court granted Studebaker’s motion to set aside the default judgment but denied the motion to dismiss. At June 30, 2021, the $<span id="xdx_907_ecustom--LossOnInventoryInvestment_c20210101__20210630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--StudebakerDefenseGroupLLCMember__dei--LegalEntityAxis__custom--IPSMember_zfpqKIJhLWEh" title="Loss on inventory investment">500,000</span> was recorded as Loss on Inventory Investment. The Company won this case but has not collected any settlement yet, another lawsuit was filed to collect.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On April 13, 2023, a settlement was reached in the Studebaker and IPS legal case. The court found in favor of IPS and ordered Studebaker to pay $<span id="xdx_90F_eus-gaap--LitigationSettlementAmountAwardedToOtherParty_c20230412__20230413_zJixmB8bGf8b">550,000</span> to IPS. The payments were to commence on May 1, 2023 and continue monthly in 17 instalments until the full amount is paid in full but as of the filing date, no payment has been received by IPS.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>GSG PPE, LLC</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On November 19, 2021, IPS filed a complaint against GSG PPE, LLC (“GSG”) and Gary Waxman (“Waxman”), the owner, alleging three counts of breach of contract for a purchase agreement, a promissory note, and a personal guaranty. Collectively, the company alleges that GSG and Waxman have materially breached all three contracts. In late 2020, GSG and IPS executed a valid initial contract setting the terms of a business transaction. GSG failed to pay IPS approximately 75% of the amount owed to IPS. GSG acknowledged it owed the money and executed a promissory note in favor of IPS in the amount of $<span id="xdx_900_eus-gaap--DebtInstrumentFaceAmount_iI_c20211119__dei--LegalEntityAxis__custom--IPSMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GSGPPELLCMember__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember_zjI15oe2Lnii" title="Principal amount">630,000</span> which matured on <span id="xdx_904_eus-gaap--DebtInstrumentMaturityDate_dd_c20211119__20211119__dei--LegalEntityAxis__custom--IPSMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GSGPPELLCMember__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember_zEyQly21T3w2" title="Maturity date">September 30, 2021</span>. The note provides for attorney fees and interest in addition to the $<span id="xdx_90F_eus-gaap--DebtInstrumentFaceAmount_iI_c20211119__dei--LegalEntityAxis__custom--IPSMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GSGPPELLCMember__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember_zoMcKXGfjvzg" title="Note principal amount">630,000</span>. Waxman’s personal guaranty confirmed that GSG owed IPS $<span id="xdx_903_eus-gaap--OtherReceivables_iI_c20211119__dei--LegalEntityAxis__custom--IPSMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GSGPPELLCMember__srt--TitleOfIndividualAxis__custom--WaxmanMember_zmKzX0p3pvh2" title="Due from related party">630,000</span>. On September 30, 2021, the $<span id="xdx_906_eus-gaap--ProvisionForDoubtfulAccounts_c20210930__20210930__dei--LegalEntityAxis__custom--IPSMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GSGPPELLCMember_zYbzPqEhem6d" title="Bad debt expenses">630,000</span> was recorded as Bad Debt Expense. A settlement was entered into between the parties in June 2022, whereby GSG and Waxman agreed to pay $<span id="xdx_906_eus-gaap--LitigationSettlementAmountAwardedToOtherParty_c20220601__20220630__dei--LegalEntityAxis__custom--IPSMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GSGPPELLCMember__srt--TitleOfIndividualAxis__custom--WaxmanMember_zoKvnydYAXj1" title="Litigation settlement amount">743,000</span> which included attorney fees and interest, which is required to be paid to the Company in monthly instalments over 17 months. The Company received additional monthly instalment payments as part of the agreement through January 2023. As of September 30, 2024, and through the date of this filing, the Company has not received the monthly installment payments due to the Company from GSG since January of 2023.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Exclusive License and Commercial Agreements</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Scienture entered into an exclusive license and commercial agreement with Kesin Pharma Corporation (“Kesin”) whereby Scienture granted the exclusive license rights to commercialize SCN-102 in 2022 and SCN-104 in 2023 to Kesin (SCN-102 and SCN-104 are together referred to as “the Products”) for use in the United States of America.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In March 2024, the parties terminated the agreement, and the parties agreed that Scienture shall pay Kesin a total gross amount of $<span id="xdx_909_eus-gaap--LossOnContractTerminationForDefault_c20240301__20240331__us-gaap--TypeOfArrangementAxis__custom--ExclusiveLicenseAndCommercialAgreementsMember_zXF5lGH6UpDh" title="Total gross amount">1,285,000</span> upon commercialization of product via a royalty arrangement.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This agreement also requires that if <span id="xdx_902_eus-gaap--ContractTerminationClaimsDescription_c20240301__20240331__us-gaap--TypeOfArrangementAxis__custom--ExclusiveLicenseAndCommercialAgreementsMember_zl2R4jDmXXy3" title="Contract termination claims, description">the full $1,285,900 has not been repaid within two years of the early of i) commercial launch or ii) 120 from FDA approval, then interest will accrue prospectively at a rate of 8% annually on unpaid balance. Accordingly, Scienture recorded a $1,285,000 termination fee liability</span>. As of September 30, 2024, the entire amount is outstanding.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In August 2024, Kesin demanded immediate payment of the full amount under the Kesin Termination Agreement, alleging the full amount is payable in connection with the consummation Scienture’s business combination with the Company. Scienture has disputed that the amount is now payable, and the parties are in discussions to resolve the issue. There can be no assurance that an amicable resolution will be obtained. If Kesin brings a legal action, Scienture will vigorously defend it.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023Q2	us-gaap	Litigation Settlement Amount Awarded To Other Party LitigationSettlementAmountAwardedToOtherParty	550000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	20633	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	83538	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	73084	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	56919	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	48612	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	282786	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	48538	usd
CY2024Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	234248	usd
CY2024Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	60882	usd
CY2024Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	173366	usd
CY2024Q3	us-gaap	Disposal Group Including Discontinued Operation Other Expense DisposalGroupIncludingDiscontinuedOperationOtherExpense	62656	usd
	us-gaap	Disposal Group Including Discontinued Operation Other Expense DisposalGroupIncludingDiscontinuedOperationOtherExpense	187968	usd
CY2024Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	64861	usd
CY2024Q3	us-gaap	Gross Profit GrossProfit	3883	usd
CY2024Q3	us-gaap	Assets Assets	94259693	usd
CY2024Q3	us-gaap	Profit Loss ProfitLoss	-3183601	usd
CY2024Q3	us-gaap	Cost Of Revenue CostOfRevenue	60978	usd
CY2023Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	392286	usd
CY2023Q3	us-gaap	Gross Profit GrossProfit	39592	usd
CY2023Q3	us-gaap	Assets Assets	21653843	usd
CY2023Q3	us-gaap	Profit Loss ProfitLoss	-3525114	usd
CY2023Q3	us-gaap	Cost Of Revenue CostOfRevenue	352694	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	83560	usd
	us-gaap	Gross Profit GrossProfit	3180	usd
CY2024Q3	us-gaap	Assets Assets	94259693	usd
	us-gaap	Profit Loss ProfitLoss	16228530	usd
	us-gaap	Cost Of Revenue CostOfRevenue	80380	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1235168	usd
	us-gaap	Gross Profit GrossProfit	162990	usd
CY2023Q3	us-gaap	Assets Assets	21653843	usd
	us-gaap	Profit Loss ProfitLoss	-6177945	usd
	us-gaap	Cost Of Revenue CostOfRevenue	1072178	usd
CY2024Q3	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2024Q3	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q3	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2024Q3	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false

Files In Submission

Name	View Source	Status
0001493152-24-043756-index-headers.html	Edgar Link	pending
0001493152-24-043756-index.html	Edgar Link	pending
0001493152-24-043756.txt	Edgar Link	pending
0001493152-24-043756-xbrl.zip	Edgar Link	pending
ex10-5.htm	Edgar Link	pending
ex3-1.htm	Edgar Link	pending
ex3-1_001.jpg	Edgar Link	pending
ex3-1_002.jpg	Edgar Link	pending
ex3-1_003.jpg	Edgar Link	pending
ex3-1_004.jpg	Edgar Link	pending
ex3-1_005.jpg	Edgar Link	pending
ex3-1_006.jpg	Edgar Link	pending
ex3-1_007.jpg	Edgar Link	pending
ex3-1_008.jpg	Edgar Link	pending
ex3-1_009.jpg	Edgar Link	pending
ex3-1_010.jpg	Edgar Link	pending
ex3-1_011.jpg	Edgar Link	pending
ex3-1_012.jpg	Edgar Link	pending
ex3-1_013.jpg	Edgar Link	pending
ex3-1_014.jpg	Edgar Link	pending
ex3-1_015.jpg	Edgar Link	pending
ex3-2.htm	Edgar Link	pending
ex3-2_001.jpg	Edgar Link	pending
ex3-2_002.jpg	Edgar Link	pending
ex3-2_003.jpg	Edgar Link	pending
ex3-2_004.jpg	Edgar Link	pending
ex3-2_005.jpg	Edgar Link	pending
ex3-2_006.jpg	Edgar Link	pending
ex3-2_007.jpg	Edgar Link	pending
ex3-2_008.jpg	Edgar Link	pending
ex3-2_009.jpg	Edgar Link	pending
ex3-2_010.jpg	Edgar Link	pending
ex3-2_011.jpg	Edgar Link	pending
ex3-2_012.jpg	Edgar Link	pending
ex3-2_013.jpg	Edgar Link	pending
ex3-2_014.jpg	Edgar Link	pending
ex3-2_015.jpg	Edgar Link	pending
ex3-2_016.jpg	Edgar Link	pending
ex3-2_017.jpg	Edgar Link	pending
ex3-2_018.jpg	Edgar Link	pending
ex3-2_019.jpg	Edgar Link	pending
ex3-2_020.jpg	Edgar Link	pending
ex3-2_021.jpg	Edgar Link	pending
ex3-2_022.jpg	Edgar Link	pending
ex3-2_023.jpg	Edgar Link	pending
ex3-2_024.jpg	Edgar Link	pending
ex3-2_025.jpg	Edgar Link	pending
ex3-2_026.jpg	Edgar Link	pending
ex3-2_027.jpg	Edgar Link	pending
ex3-2_028.jpg	Edgar Link	pending
ex3-2_029.jpg	Edgar Link	pending
ex3-2_030.jpg	Edgar Link	pending
ex3-2_031.jpg	Edgar Link	pending
ex3-2_032.jpg	Edgar Link	pending
ex3-2_033.jpg	Edgar Link	pending
ex3-2_034.jpg	Edgar Link	pending
ex3-2_035.jpg	Edgar Link	pending
ex3-2_036.jpg	Edgar Link	pending
ex3-2_037.jpg	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex32-2.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
form10-q_001.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
form10-q_htm.xml	Edgar Link	completed
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
scnx-20240930.xsd	Edgar Link	pending
Show.js	Edgar Link	pending
scnx-20240930_cal.xml	Edgar Link	unprocessable
scnx-20240930_def.xml	Edgar Link	unprocessable
scnx-20240930_lab.xml	Edgar Link	unprocessable
scnx-20240930_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$SCNX
Scienture Holdings, Inc. Stock $scnx

2024 Q4 Form 10-Q Financial Statement

#000149315224043756 Filed on November 06, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SCNX Scienture Holdings, Inc. Stock $scnx

2024 Q4 Form 10-Q Financial Statement

#000149315224043756 Filed on November 06, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SCNX
Scienture Holdings, Inc. Stock $scnx